<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02161952</url>
  </required_header>
  <id_info>
    <org_study_id>IBMMTG.05</org_study_id>
    <secondary_id>HCG, No. Registry 505/05</secondary_id>
    <nct_id>NCT02161952</nct_id>
  </id_info>
  <brief_title>Pirfenidone, an Antifibrotic and Antiinflammatory Drug</brief_title>
  <official_title>Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cell Therapy And Technology, S.a. De C.v.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to assess whether two-year treatment with Pirfenidone influence
      necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis staging</measure>
    <time_frame>24 months</time_frame>
    <description>Fibrosis was evaluated according to Ishak fibrosis staging scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade of necroinflammation activity</measure>
    <time_frame>24 months</time_frame>
    <description>Necroinflammatory activity was evaluated according to the Ishak modified histological activity index (HAI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Fibrosis</condition>
  <condition>Hepatitis C Chronic</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched equivalent placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched equivalent placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>5 methyl-1-phenil-2 (1H)-pyridone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched equivalent placebo</intervention_name>
    <arm_group_label>Matched equivalent placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with established advanced liver disease caused by hepatitis C virus (HCV)
             chronic infection defined by a positive test for anti-HCV antibodies and detectable
             serum HCV RNA (Amplicor HCV 2.0 polymerase chain reaction (PCR) assay).

          -  Sign an informed consent form to allow the collection of liver biopsies before and
             after treatment.

          -  No antifibrotic, antiviral or immunosuppressive drugs for at least 6 months before
             starting pirfenidone therapy.

          -  No alcohol intake for at least 6 months before nor during Pirfenidone (PFD) treatment.

        Exclusion Criteria:

          -  Patients with clinical contraindications to hepatic biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Armendariz-Borunda, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head, Molecular Biology and Genomics Department</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Juan Armend√°riz-Borunda</investigator_full_name>
    <investigator_title>Head, Molecular Biology and Genomics Department, CUCS</investigator_title>
  </responsible_party>
  <keyword>Fibrosis, necroinflammation, hepatitis C chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

